3
Announcements
Trials
Browse
Landscape
Status
Completed
4
Withdrawn
3
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Follicular
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hereditary Sensory and Autonomic Neuropathies
2
Squamous Cell Carcinoma of Head and Neck
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Rituximab
66
Cyclophosphamide
52
fludarabine phosphate
26
fludarabine
22
Filgrastim
21
Vincristine
19
Methotrexate
19
Melphalan
19
Doxorubicin
18
Radiotherapy
17
Etoposide
17
Prednisone
16
Tacrolimus
15
Whole-Body Irradiation
14
Mycophenolic Acid
14
Cytarabine
14
Peripheral Blood Stem Cell Transplantation
13
Gemcitabine
13
Cyclosporine
13
Antilymphocyte Serum
13
Lenalidomide
12
Busulfan
11
Bortezomib
11
Granulocyte Colony-Stimulating Factor
9
Alemtuzumab
9
sargramostim
8
Dexamethasone
8
Cord Blood Stem Cell Transplantation
8
pembrolizumab
7
ibritumomab tiuxetan
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma
×
duvelisib
×
Clear all
NCT04342117
2021-03-17
REAL
SecuraBio
Terminated
2 enrolled